(NASDAQ: BNTC) Benitec Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Benitec Biopharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast BNTC's revenue for 2028 to be $364,904,951, with the lowest BNTC revenue forecast at $110,690,962, and the highest BNTC revenue forecast at $619,118,940. On average, 2 Wall Street analysts forecast BNTC's revenue for 2029 to be $1,773,752,312, with the lowest BNTC revenue forecast at $1,436,168,329, and the highest BNTC revenue forecast at $2,111,336,294.
In 2030, BNTC is forecast to generate $5,782,664,706 in revenue, with the lowest revenue forecast at $2,773,136,919 and the highest revenue forecast at $8,792,192,492.